Literature DB >> 26191800

The current managements of pancreatic diabetes in Japan.

Ken Kawabe1, Tetsuhide Ito2, Hisato Igarashi1, Ryoichi Takayanagi1.   

Abstract

Pancreatic diabetes is secondary diabetes followed by progressions of pancreatic exocrine diseases, such as chronic pancreatitis, pancreatic neoplasm and post-pancreatectomy. Because of destruction and reduction of the pancreatic endocrine and exocrine functional compartments, patients with pancreatic diabetes frequently show malnutrition from maldigestion and malabsorption by insufficiencies in pancreatic digestive enzymes, and show unstable glycemic control and prolonged hypoglycemia by insufficiencies in synthesis and secretion of insulin and glucagon. Epidemiological studies have suggested that the incidence and development of pancreatic diabetes in patients with chronic pancreatitis (CP) depends on several risk factors, such as alcohol intake, the presence of pancreatic calcification and the long-term duration of CP. The clinical management of pancreatic diabetes is divided into two parts: one is the supplementation of pancreatic digestive enzymes and the other is the achievement of appropriate glycemic control. The appropriate and sufficient pancreatic exocrine replacement therapy is important for the maintenance of better nutrient conditions for patients with pancreatic diabetes. Furthermore, the intensive insulin therapy combined with short- or ultra-short-acting insulin and long-acting insulin glargine can be achieved for stable glycemic control and reduction of severe frequent hypoglycemia in patients with pancreatic diabetes. These current advanced management techniques against insufficiencies of pancreatic exocrine endocrine functions are beneficial for improving and maintaining the quality of life in patients with pancreatic diabetes.

Entities:  

Keywords:  Chronic pancreatitis; Glargine; Insulin; Pancreatic diabetes; Pancreatic digestive enzymes

Year:  2009        PMID: 26191800     DOI: 10.1007/s12328-008-0052-x

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  23 in total

1.  Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. HOE 901/3002 Study Group.

Authors:  H Yki-Järvinen; A Dressler; M Ziemen
Journal:  Diabetes Care       Date:  2000-08       Impact factor: 19.112

2.  Correlation between pancreatic endocrine and exocrine function and characteristics of pancreatic endocrine function in patients with diabetes mellitus owing to chronic pancreatitis.

Authors:  T Nakamura; K Imamura; K Takebe; A Terada; Y Arai; Y Tandoh; N Yamada; M Ishii; K Machida; T Suda
Journal:  Int J Pancreatol       Date:  1996-12

3.  Morphological study of pancreatic endocrine in an experimental chronic pancreatitis with diabetes induced by stress and cerulein.

Authors:  T Miyahara; M Kawabuchi; M Goto; I Nakano; O Nada; H Nawata
Journal:  Ultrastruct Pathol       Date:  1999 May-Jun       Impact factor: 1.094

Review 4.  Exocrine and endocrine pancreatic insufficiency after pancreatic surgery.

Authors:  Stefan Kahl; Peter Malfertheiner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2004-10       Impact factor: 3.043

5.  Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. The European Study Group of HOE 901 in type 1 diabetes.

Authors:  T R Pieber; I Eugène-Jolchine; E Derobert
Journal:  Diabetes Care       Date:  2000-02       Impact factor: 19.112

6.  Study of porcine and human isophane (NPH) insulins in normal subjects.

Authors:  D R Owens; I R Jones; A J Birtwell; C T Burge; S Luzio; C J Davies; P Heyburn; L G Heding
Journal:  Diabetologia       Date:  1984-04       Impact factor: 10.122

7.  Clinical and hormonal aspects of pancreatic diabetes.

Authors:  S Bank; I N Marks; A I Vinik
Journal:  Am J Gastroenterol       Date:  1975-07       Impact factor: 10.864

8.  Pancreatic diabetes in a follow-up survey of chronic pancreatitis in Japan.

Authors:  Tetsuhide Ito; Makoto Otsuki; Takao Itoi; Tooru Shimosegawa; Akihiro Funakoshi; Keiko Shiratori; Satoru Naruse; Yoshikazu Kuroda
Journal:  J Gastroenterol       Date:  2007-04-26       Impact factor: 7.527

Review 9.  Pancreatic diabetes mellitus.

Authors:  R J Sjoberg; G S Kidd
Journal:  Diabetes Care       Date:  1989 Nov-Dec       Impact factor: 19.112

10.  Comparison of pharmacokinetics and dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes: a double-blind, randomized, crossover study.

Authors:  Francesca Porcellati; Paolo Rossetti; Natalia Ricci Busciantella; Stefania Marzotti; Paola Lucidi; Steven Luzio; David R Owens; Geremia B Bolli; Carmine G Fanelli
Journal:  Diabetes Care       Date:  2007-07-10       Impact factor: 19.112

View more
  3 in total

1.  Evidence-based clinical practice guidelines for chronic pancreatitis 2015.

Authors:  Tetsuhide Ito; Hiroshi Ishiguro; Hirotaka Ohara; Terumi Kamisawa; Junichi Sakagami; Naohiro Sata; Yoshifumi Takeyama; Morihisa Hirota; Hiroyuki Miyakawa; Hisato Igarashi; Lingaku Lee; Takashi Fujiyama; Masayuki Hijioka; Keijiro Ueda; Yuichi Tachibana; Yoshio Sogame; Hiroaki Yasuda; Ryusuke Kato; Keisho Kataoka; Keiko Shiratori; Masanori Sugiyama; Kazuichi Okazaki; Shigeyuki Kawa; Yusuke Tando; Yoshikazu Kinoshita; Mamoru Watanabe; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2016-01-04       Impact factor: 7.527

Review 2.  Less common etiologies of exocrine pancreatic insufficiency.

Authors:  Vikesh K Singh; Mark E Haupt; David E Geller; Jerry A Hall; Pedro M Quintana Diez
Journal:  World J Gastroenterol       Date:  2017-10-21       Impact factor: 5.742

Review 3.  Evidence-based clinical practice guidelines for chronic pancreatitis 2021.

Authors:  Kyoko Shimizu; Tetsuhide Ito; Atsushi Irisawa; Takao Ohtsuka; Hirotaka Ohara; Atsushi Kanno; Mitsuhiro Kida; Junichi Sakagami; Naohiro Sata; Yoshifumi Takeyama; Junko Tahara; Morihisa Hirota; Nao Fujimori; Atsushi Masamune; Satoshi Mochida; Nobuyuki Enomoto; Tooru Shimosegawa; Kazuhiko Koike
Journal:  J Gastroenterol       Date:  2022-08-22       Impact factor: 6.772

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.